Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Carveda-N
- Development stage
- Unknown
- Lead developer
- Ferozsons Group
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Carveda-N** is an oral fixed-dose cardiovascular combination marketed by Ferozsons Laboratories. It contains **carvedilol**, a nonselective beta-adrenergic and alpha-1-adrenergic receptor blocker that lowers heart rate, myocardial workload, and peripheral vascular resistance, plus **ivabradine**, a selective inhibitor of the sinoatrial-node hyperpolarization-activated cyclic nucleotide-gated channel current that reduces heart rate without directly reducing myocardial contractility. Ferozsons describes the product as supporting heart-rate control and reducing cardiac strain; the combination is used as substitution therapy in patients already controlled on the individual components for chronic heart failure with systolic dysfunction or chronic stable angina pectoris. ([ferozsons-labs.pk](https://ferozsons-labs.pk/products/carveda-n-12.5mg-5mg))
- Brand names
- Carveda-N
- Other names
- Carveda Ncarvedilol + ivabradine
02
Targets
ADRA1A (α1A)ADRB2 (β2)ADRB1 (β1)LTCC (Voltage-gated calcium channel (L-type))
Beyond the preview
Go deeper on Carveda-N.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Carveda-N.